We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher (DHR) Tops Q3 Earnings, Revenues Miss, Guides Up
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) is a global conglomerate that designs, manufactures and markets diverse lines of professional, medical, industrial, commercial and consumer products. The company organizes its businesses into five operating segments – The Test & Measurement segment, The Environmental segment, The Life Sciences & Diagnostics segment, The Dental segment and Industrial Technologies segment.
Danaher’s tried and tested business model – the Danaher Business System (‘DBS’) – has proved to be the fundamental growth driver, fueling revenue, margins, cash flow and earnings improvement. Also the company has significantly expanded its foothold in the healthcare and dental markets over the past few quarters and they are proving to be major profit churners. Furthermore, Danaher’s previously completed acquisitions significantly drive its top-line growth.
Positive industry trends, such as rise in aging population, increased spending on healthcare and fitness as well as favorable regulations from the Chinese Food and Drug Administration, are bolstering growth of the healthcare portfolio.
Danaher has a decent earnings surprise history, beating estimates three times over the trailing four quarters. The stock has an average positive surprise of 5.1%.
Key Stats: Concurrent with the earnings release, Danaher raised its adjusted earnings guidance to $3.57 to $3.61 from the previous range of $3.53 to $3.60. Overall, the company reported impressive key metrics largely driven by its effective business model, the Danaher Business System (“DBS”), which focuses on three critical areas -- quality, delivery, and cost & innovation.
Stock Price: Share prices moved up in the pre-market trading probably on account of this healthy beat.
Check back later for our full write up on this DHR earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Danaher (DHR) Tops Q3 Earnings, Revenues Miss, Guides Up
Danaher Corporation (DHR - Free Report) is a global conglomerate that designs, manufactures and markets diverse lines of professional, medical, industrial, commercial and consumer products. The company organizes its businesses into five operating segments – The Test & Measurement segment, The Environmental segment, The Life Sciences & Diagnostics segment, The Dental segment and Industrial Technologies segment.
Danaher’s tried and tested business model – the Danaher Business System (‘DBS’) – has proved to be the fundamental growth driver, fueling revenue, margins, cash flow and earnings improvement. Also the company has significantly expanded its foothold in the healthcare and dental markets over the past few quarters and they are proving to be major profit churners. Furthermore, Danaher’s previously completed acquisitions significantly drive its top-line growth.
Positive industry trends, such as rise in aging population, increased spending on healthcare and fitness as well as favorable regulations from the Chinese Food and Drug Administration, are bolstering growth of the healthcare portfolio.
Danaher has a decent earnings surprise history, beating estimates three times over the trailing four quarters. The stock has an average positive surprise of 5.1%.
Currently, DHR has a Zacks Rank #2 (Buy) but that could change following its third quarter 2016 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key details from the just-released announcement below:
Earnings: Adjusted earnings per share for the third-quarter 2016 came in at 87 cents, which beat the Zacks Consensus Estimate of 83 cents.
Revenue: Revenues of $4,132 million missed the Zacks Consensus Estimate of $4,149 million.
DANAHER CORP Price and EPS Surprise
DANAHER CORP Price and EPS Surprise | DANAHER CORP Quote
Key Stats: Concurrent with the earnings release, Danaher raised its adjusted earnings guidance to $3.57 to $3.61 from the previous range of $3.53 to $3.60. Overall, the company reported impressive key metrics largely driven by its effective business model, the Danaher Business System (“DBS”), which focuses on three critical areas -- quality, delivery, and cost & innovation.
Stock Price: Share prices moved up in the pre-market trading probably on account of this healthy beat.
Check back later for our full write up on this DHR earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>